We are live on ! Find out more
II

Ishara Investments Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+20.83%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$30.5M
Cap. Flow
+$13.3M
Cap. Flow %
9.77%
Top 10 Hldgs %
50.98%
Holding
53
New
16
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.31M
2
INSM icon
Insmed
INSM
+$6.21M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.33M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.97M
5
TNXP icon
Tonix Pharmaceuticals
TNXP
+$4.36M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$5.57M
2
FOLD
Amicus Therapeutics
FOLD
+$5.34M
3
AXSM icon
Axsome Therapeutics
AXSM
+$5.33M
4
VSTM icon
Verastem
VSTM
+$4.35M
5
ARWR icon
Arrowhead Research
ARWR
+$3.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
51
PUT
Praxis Precision Medicines
PRAX
$10.5B
– –
-20,500
Closed -$6.6M
PTCT icon
52
PTC Therapeutics
PTCT
$6.07B
– –
-10,250
Closed -$698K
VSTM icon
53
Verastem
VSTM
$665M
– –
-820,000
Closed -$4.35M
1 2
3

Similar funds

SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
GBFP
Golden Bell Financial Planning Alpharetta, Georgia $136M AUM 12.99% 1-Year Est. Return
RIA
Rhodes Investment Advisors Fort Worth, Texas $136M AUM
RCWM
Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
HMS
Hanseatic Management Services Albuquerque, New Mexico $136M AUM

Ishara Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Ishara Investments held 53 positions worth $136M, up 29% from $106M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Ishara Investments deployed $13.3M of net new capital in Q2 2026, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Insmed: 51,250 shares worth $5.46M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $5.33M trimmed.

  • Ishara Investments's largest Q2 2026 buy was Insmed: 51,250 shares worth $5.46M.
  • Ishara Investments added most to Acadia Pharmaceuticals in Q2 2026, an estimated $6.31M increase.
  • Ishara Investments's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.33M.
  • Ishara Investments fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $5.57M.
  • Ishara Investments's ten largest holdings make up 51% of its $136M portfolio in Q2 2026.
  • Ishara Investments opened 16 new positions and closed 12 in Q2 2026.
  • Ishara Investments's portfolio value rose 29% quarter-over-quarter to $136M.

Based on Ishara Investments's 13F filing for Q2 2026, filed 14 Aug 2026.